Specific Patient Populations Benefit from Nivolumab/Ipilimumab Combo Therapy

At the 2019 American Society of Clinical Oncology Annual Meeting, Michael Atkins, MD, director at the Georgetown Lombardi Cancer Center, discussed what pharmacists should know about nivolumab/ipilimumab combination therapy in advanced melanoma.

At the 2019 American Society of Clinical Oncology Annual Meeting, Michael Atkins, MD, director at the Georgetown Lombardi Cancer Center, discussed what pharmacists should know about nivolumab/ipilimumab combination therapy in advanced melanoma.

Transcript

The specific implications for pharmacists are that there are patient populations where it appears that combination therapy of nivolumab and ipilimumab is required to attain maximum benefit, and that includes patients with brain metastases. And it also looks like the durable off treatment responses are going to be more likely in patients that receive combination immunotherapy, and therefore, pharmacists should be prepared to be giving prescriptions or filling prescriptions for the combination of nivolumab and ipilimumab for their patients with myeloma and look to see how those combinations may actually benefit patients with other cancers that respond to single agent PD1.

Read more about the long-term follow-up study results for nivolumab/ipilimumab in advanced melanoma here.